Resolution Therapeutics Announces Approval of Clinical Trial ...

4 days ago · Edinburgh and London, UK, 19 November 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company pioneering regenerative …

CouponFollow Extension

£63
OFF

Resolution Therapeutics Announces New Clinical And Preclinical …

6 days from now

Nov 11, 2024 · Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment Resolution Therapeutics Limited ("Resolution"), a clinical-stage …

prnewswire.com

£63
OFF

Resolution Therapeutics Announces New Breakthrough Clinical …

6 days from now

Jun 5, 2024 · Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment Resolution Therapeutics Limited ("Resolution"), a clinical-stage …

prnewswire.com

FAQs about Resolution Therapeutics Announces Approval of Clinical Trial ... Coupon?

Who is resolution Therapeutics?

Resolution Therapeutics was formed based on these early findings and in June this year the company received approval to begin a phase 1/2 study of RTX001 in patients with decompensated liver cirrhosis. The EMERALD trial will be carried out in the UK and Spain and plans to start patient recruitment before the end of the year. ...

When will resolution Therapeutics start recruiting patients in Spain?

It is expected to start recruiting patients in Spain in the second quarter of 2025. Dr Clifford Brass, Chief Medical Officer of Resolution Therapeutics, commented: "We are excited to have received approval from the AEMPS to expand our Phase 1/2 EMERALD study for RTX001 into Spain. ...

Does resolution Therapeutics secure Spanish liver disease trial approval?

"Resolution Therapeutics secures Spanish liver disease trial approval" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. ...

When did resolution Therapeutics get MHRA approval?

Resolution Therapeutics approval from the MHRA follows the presentation of key proof of concept data by the University of Edinburgh at the European Association for the Study of the Liver (EASL) Congress 2024 which took place from 5 to 8 June in Milan, Italy. Resolution Therapeutics spun out from the University of Edinburgh in 2020. ...

Will rtx001 go into clinical trials?

Resolution plans to use the new financing to progress RTX001, its lead candidate, into clinical trials. RTX001 is an engineered autologous macrophage cell therapy for treatment of end stage liver disease. ...

What is resolution's lead candidate therapy?

Resolution’s lead candidate therapy is designed to regenerate the liver in end stage liver disease patients by increasing anti-fibrotic and anti-inflammatory effects. ...